Summary

Overview
Global cannabis use disorder market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Cannabis Use Disorder (CUD) is a recognized psychiatric condition characterized by problematic and compulsive cannabis (marijuana) use, leading to clinically significant impairment or distress. It is classified as a substance use disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which is a widely used diagnostic manual in the field of mental health.
The severity of cannabis use disorder is categorized as mild, moderate, or severe, depending on the number of symptoms present. Some of the key criteria for diagnosis include impaired functioning in various aspects of life (such as work, school, or relationships) due to cannabis use, persistent desire or unsuccessful efforts to stop using, and the development of tolerance or withdrawal symptoms. Treatment options for Cannabis Use Disorder often involve a combination of behavioral therapies, counseling, and support groups to help individuals manage and overcome their problematic use of cannabis.
Market Dynamics: Drivers
The strategies adopted by the companies
The rise of strategies adopted by the companies helps to accelerates the market growth. For instance, in September 2023, Spring Health expanded of its substance use disorder (SUD) support services through a new partnership with Eleanor Health. Spring Health had partnered with Eleanor Health to ensure that all members can receive tailored care that addresses the entirety of their mental health support needs related to SUD.
This collaboration addresses a vital gap in conventional healthcare systems by delivering personalized, evidence-based care for individuals grappling with severe mental health challenges and substance use disorders. Additionally, in October 2023, the Māori Indigenous group Rangiwaho Marae and the medical cannabis grower Rua Bioscience had obtained the first-ever psilocybin cultivation license in New Zealand and will use it to help treat methamphetamine and other substance use disorders.
The company awhich marks a significant new milestone in a pre-existing collaboration between a network of traditional rongoā Māori healing practitioners, the University of Auckland and a series of other institutions and stakeholders in the country. In 2021, the United States government’s National Institutes of Health awarded approximately $4 million to Maryland’s Johns Hopkins University to study the drug’s impact on people suffering from tobacco addiction. Thus above factors helps to accelerates the market growth.
Market Dynamics: Restraints
The limitation of treatment options
There are no specific FDA-approved medications designed specifically for the treatment of cannabis use disorder. The absence of pharmacological interventions tailored to CUD can limit the treatment options available to healthcare providers and individuals seeking help. In some cases, healthcare providers may use off-label medications, such as those approved for other substance use disorders or mental health conditions, to address certain symptoms associated with CUD.
However, the effectiveness of off-label use may vary, and research on these approaches is still in progress. Behavioral therapies, such as cognitive-behavioral therapy (CBT) and contingency management, are commonly used in the treatment of CUD. While effective for many individuals, the availability of trained therapists and access to these therapies may be limited, especially in certain geographic areas.
Many individuals with CUD also have co-occurring mental health disorders or additional substance use disorders. The complexity of addressing multiple issues simultaneously can pose challenges for treatment providers, requiring a comprehensive and integrated approach. Thus above factors restrain the market growth.
Segment Analysis
The global cannabis use disorder market is segmented based on severity, treatment, end user and region.
The behavioral therapy segment from the treatment segment accounted for approximately 39.7% of Cannabis Use Disorder type share
Behavioral therapy is a common and effective approach in the treatment of Cannabis Use Disorder (CUD). Behavioral therapies focus on modifying patterns of thinking and behavior associated with substance use, helping individuals develop healthier coping mechanisms and skills to manage cravings and triggers. Cognitive-Behavioral Therapy (CBT) is a widely used therapeutic approach that addresses the relationship between thoughts, feelings, and behaviors.
In the context of CUD, CBT helps individuals identify and modify maladaptive thought patterns and behaviors associated with cannabis use. It also teaches coping strategies to manage stress and cravings. For instance, the 2021 VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders gives a “weak for” recommendation for CBT in the treatment of patients with CUD.
The MHS relies on the VA/DoD clinical practice guidelines (CPGs) to inform best clinical practices. The CPGs are developed under the purview of clinical experts and are derived through a transparent and systematic approach that includes, but is not limited to, systematic reviews of the literature on a given
topic and development of recommendations using a graded system that takes into account the overall quality of the evidence and the magnitude of the net benefit of the recommendation.
Additionally, in some cases, involving family members in the therapeutic process can be beneficial. Family-based therapy addresses family dynamics, communication patterns, and support systems to create a more conducive environment for recovery. Thus above factors boost the segment growth.
Geographical Analysis
North America accounted for approximately 42.4% of the market share in 2022
North America is expected to create the opportunities for cannabis use disorder treatment. The ease of access to cannabis products, both legally and illegally, can influence patterns of use. Increased availability, whether through legal dispensaries or the illicit market, may contribute to higher rates of cannabis use and potential development of Cannabis Use Disorder.
For instance, according to National Center for Drug Abuse Statistics, estimated that approximately half of Americans, some 78 million people, claimed to have used marijuana at some point in their lifetime. The 55 million amount is actually higher than the number of active tobacco smokers, which is approximately 36.5 million.
The rising popularity of marijuana can be attributed to its growing acceptability in modern society. Marijuana is widely accepted as being “less risky” than other substances like tobacco, alcohol, or painkillers. Additionally, social and cultural factors, including the normalization of cannabis use in certain communities, can influence patterns of use.
Changes in societal attitudes and increased social acceptance may contribute to a higher prevalence of cannabis use, including problematic use. Early initiation of cannabis use during adolescence is a known risk factor for the development of Cannabis Use Disorder. Changes in attitudes and perceptions among young people, coupled with increased availability, may contribute to higher rates of use in this demographic. Thus, above factors rise the region growth.
Market Segmentation
By Severity
• Mild
• Severe
By Treatment
• Detoxification
• Counselling & Behavioral Therapy
• Medications
• Support Group
By End User
• Hospitals and Clinics
• Rehabilitation Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Covid-19 Analysis
The COVID-19 pandemic is affecting the health of populations worldwide, including those living with mental health and substance use concerns. The COVID-19 pandemic caused disruptions to treatment of substance use disorder, the availability of drugs, and other social factors that influence drug use. In June 2020, more than 10% of adults had started or increased substance use to cope with the pandemic, which could include using cannabis.
The divergence in state-by-state policies governing cannabis sales in the U.S. could create differences in who might use cannabis and for what reasons, particularly because stress can be a catalyst for substance use. While patients with CUD had a higher prevalence of alcohol use, depressive episodes, and a history of a previous myocardial infarction, they also presented as a younger population with a lower prevalence in systemic diseases such as diabetes, hypertension, hyperlipidemia, history of cirrhosis, autoimmune conditions, and obesity.
Higher odds of developing ventricular fibrillation, ventricular tachycardia, and ischemic stroke were also revealed among the CUD population; however, a lower rate of major adverse cardiac events, mortality, and length of hospital stay was also seen within this cohort.
Competitive Landscape
The major global players in the market include Indivior PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., LGM Pharma, Pfizer Inc, F. Hoffmann-La Roche Ltd, Unichem Labs, Alkermes plc, BioCorRx Inc, Bausch Health Companies, Inc among others.
Why Purchase the Report?
• To visualize the global cannabis use disorder market segmentation based on severity, treatment, end user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cannabis use disorder market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cannabis use disorder market report would provide approximately 64tables, 61figures and 186pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Severity
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The strategies adopted by the companies
4.1.2. Restraints
4.1.2.1. The limitation of treatment options
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. SWOT Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Severity
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
7.1.2. Market Attractiveness Index, By Severity
7.2. Mild *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Severe
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Detoxification *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Counselling & Behavioral Therapy
8.4. Medications
8.5. Support Group
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Rehabilitation Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Indivior PLC.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Teva Pharmaceutical Industries Ltd
12.3. Mylan N.V.
12.4. LGM Pharma
12.5. Pfizer Inc
12.6. F. Hoffmann-La Roche Ltd
12.7. Unichem Labs
12.8. Alkermes plc
12.9. BioCorRx Inc
12.10. Bausch Health Companies, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us